← Human Trials & Peer-Reviewed Studies
The nicotine inhaler in smoking cessation.
Plain-language guide to PMID 9250233 (1997): double-blind randomized controlled trial of Therapeutic nicotine (patch, non-peptide) in 123 participants.
Key Facts
- PMID
- 9250233
- Journal
- Archives of internal medicine
- Year
- 1997
- Study type
- Randomized Controlled Trial
- Authors
- Hjalmarson A et al. (4 authors)
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.
A new method of delivering nicotine via inhaler supplies nicotine orally through inhalation from a plastic tube.
This mode of delivering nicotine resembles smoking, as it includes handling and active inhalation.
Who Took Part
The study group was 123 participants.
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
Randomization to treatment or control conditions were made at the first group session, with 123 participants receiving nicotine inhalers and 124 receiving placebo inhalers.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the participants nor the staff measuring them knew who was on Therapeutic nicotine (patch, non-peptide), so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Therapeutic nicotine (patch, non-peptide) group a baseline to be compared against.
A 1-year, randomized, double-blind, placebo-controlled study was conducted in a smoking cessation clinic.
What Was Measured
PubMed files the paper under topics including Blood Pressure, Cotinine, Lipids, Nebulizers and Vaporizers, Nicotine, Reproducibility of Results and Saliva.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 123 participants.
Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 1997 (Archives of internal medicine), a journal based in United States.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.